New studies find that biomarkers measured in early pregnancy months before standard screening can predict gestational diabetes risk with strong accuracy. The discovery has big potential for earlier interventions, better outcomes, and helping mothers avoid complications.
Glimpse:
Early screening for gestational diabetes mellitus GDM using first-trimester biomarkers like HbA1c, amino acids, fatty acids, IGF-binding proteins, inflammation markers, and extracellular circular DNA can identify high-risk women well before the standard 24–28 week window. When combined with risk factors like age, BMI, and family history, these models show strong predictive accuracy (AUC > 0.80), enabling earlier interventions to improve outcomes for mother and baby.
Imagine getting told at 10 to 14 weeks into a pregnancy that you have a significant risk for gestational diabetes months before the standard tests kick in. That’s the promise new research is bringing to the table.
Traditionally, gestational diabetes is diagnosed through an oral glucose tolerance test between about 24-28 weeks. For many, that’s already halfway through pregnancy maybe too late to avoid some damage. But several recent studies are showing that certain biomarkers available early, some even from non-fasting blood samples can offer strong signals of who’s likely to develop GDM.
Another exciting lead comes from work on molecular biomarkers. For example, “eccDNA” (extrachromosomal circular DNA) levels in plasma between 11-13 weeks gestation have been shown to differ in women who later develop GDM versus those who don’t. One specific eccDNA (from gene PRDM16) showed extremely high predictive value AUC ~0.94 for GDM risk.
Meanwhile, metabolomic profiling has revealed that certain amino acids, bile acids, and phospholipids present in early pregnancy are altered in women who go on to develop GDM. Some of these are mediated by liver fat accumulation steatosis, showing that metabolic health even before or early in pregnancy plays a key role.
What all this means is that early screening using these biomarkers could shift the paradigm: instead of waiting until mid-pregnancy when more harm may already have occurred, clinicians could identify high risk sooner, offer nutrition/lifestyle guidance, monitor more aggressively, and perhaps prevent or reduce the severity of GDM and its complications for both mother and baby.
“Early pregnancy biomarkers are like early warning lights. If we listen sooner, we can steer the journey differently help mothers avoid risks rather than playing catch-up later.”
By
HB Team
